FREE SHIPPING over $40
OVER 9000 FIVE-STAR REVIEWS
5% OFF ALL SUBSCRIPTIONS
100% HAPPINESS GUARANTEE
Analyze Diet
0
Home / Equine Research Bank / J Orthop Res / Platelet-rich plasma lysate displays antibiofilm properties ...
Journal of orthopaedic research : official publication of the Orthopaedic Research Society2020; 38(6); 1365-1374; doi: 10.1002/jor.24584

Platelet-rich plasma lysate displays antibiofilm properties and restores antimicrobial activity against synovial fluid biofilms in vitro.

Abstract: Infectious arthritis is difficult to treat in both human and veterinary clinical practice. Recent literature reports Staphylococcus aureus as well as other gram-positive and gram-negative isolates forming free-floating biofilms in both human and equine synovial fluid that are tolerant to traditional antimicrobial therapy. Using an in vitro equine model, we investigated the ability of platelet-rich plasma (PRP) formulations to combat synovial fluid biofilm aggregates. Synovial fluid was infected, and biofilm aggregates allowed to form over a 2-hour period. PRP was collected and processed into different formulations by platelet concentration, leukocyte presence, and activation or lysis. Infected synovial fluid was treated with different PRP formulations with or without aminoglycoside cotreatment. Bacterial load (colony-forming unit/mL) was determined by serial dilutions and plate counting at 8 hours posttreatment. All PRP formulations displayed antimicrobial properties; however, formulations containing higher concentrations of platelets without leukocytes had increased antimicrobial activity. Lysis of PRP and pooling of the PRP lysate (PRP-L) from multiple horses as compared to individual horses further increased antimicrobial activity. This activity was lost with the removal of the plasma component or inhibition of the proteolytic activity within the plasma. Fractionation of pooled PRP-L identified the bioactive components to be cationic and low-molecular weight (<10 kDa). Overall, PRP-L exhibited synergism with amikacin against aminoglycoside tolerant biofilm aggregates with greater activity against gram-positive bacteria. In conclusion, the use of PRP-L has the potential to augment current antimicrobial treatment regimens which could lead to a decrease in morbidity and mortality associated with infectious arthritis.
© 2020 Orthopaedic Research Society. Published by Wiley Periodicals, Inc.
Get Full Text
Publication Date: 2020-01-14 PubMed ID: 31922274PubMed Central: PMC8018705DOI: 10.1002/jor.24584Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
LinkedInCopy
  • Journal Article
  • Research Support
  • Non-U.S. Gov't

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

The research demonstrates the antibiofilm properties of platelet-rich plasma lysate (PRP-L) when used against biofilms in synovial fluid, the liquid in joints. The study reveals that PRP-L exhibits increased effectiveness against infectious arthritis when used in the presence of a certain antibiotic, particularly on certain bacteria species.

Research Methods

  • An in vitro model replicating an equine (horse) joint environment was established, testing the behavior of synovial fluid biofilms, the stubborn layers of bacteria found in infectious arthritis.
  • Synovial fluid was deliberately infected, causing biofilm aggregates to form over a two-hour period.
  • Platelet-rich plasma (PRP) was collected and processed under varying conditions such as platelet concentration, the presence of white blood cells (leukocytes) and the use of an activation or lysis process.
  • Different PRP sets were then applied to the infected synovial fluid. Additionally, a common antibiotic class, aminoglycoside, was tested with PRP-L.
  • The bacterial load was then assessed eight hours after treatment using colony-forming unit measurements via dilutions and plate counting methods.

Key Findings

  • All PRP formulations used in the study exhibited some level of antibacterial properties.
  • The PRP lacking leukocytes and having higher platelet concentrates were found to have superior antimicrobial activity.
  • The process of platelet lysis, or breakdown, and the pooling of PRP lysate (PRP-L) from different sources resulted in further enhancement of antimicrobial traits.
  • The plasma component and the proteolytic activity within the plasma were identified as crucial to antimicrobial activity since their removal resulted in the loss of such antimicrobial properties.
  • The bioactive, or functioning, components of pooled PRP-L were identified to be cationic, holding a positive charge, and of a low molecular weight.
  • The PRP-L displayed enhanced effectiveness when used in conjunction with amikacin, a type of aminoglycoside antibiotic, revealing a synergistic relationship, particularly against gram-positive bacteria.

Conclusion

The use of PRP-L, either alone or in combination with antibiotics, might be valuable in treating types of infectious arthritis, and could lead to reduced morbidity and mortality rates among affected populations.

Cite This Article

APA
Gilbertie JM, Schaer TP, Schubert AG, Jacob ME, Menegatti S, Ashton Lavoie R, Schnabel LV. (2020). Platelet-rich plasma lysate displays antibiofilm properties and restores antimicrobial activity against synovial fluid biofilms in vitro. J Orthop Res, 38(6), 1365-1374. https://doi.org/10.1002/jor.24584

Publication

Journal of orthopaedic research : official publication of the Orthopaedic Research Society
ISSN: 1554-527X
NlmUniqueID: 8404726
Country: United States
Language: English
Volume: 38
Issue: 6
Pages: 1365-1374

Researcher Affiliations

Gilbertie, Jessica M
  • Department of Clinical Sciences, College of Veterinary Medicine, North Carolina State University, Raleigh, North Carolina.
  • Comparative Medicine Institute, North Carolina State University, Raleigh, North Carolina.
  • Department of Clinical Studies New Bolton Center, School of Veterinary Medicine, University of Pennsylvania, Kennett Square, Pennsylvania.
Schaer, Thomas P
  • Department of Clinical Studies New Bolton Center, School of Veterinary Medicine, University of Pennsylvania, Kennett Square, Pennsylvania.
Schubert, Alicia G
  • Department of Clinical Sciences, College of Veterinary Medicine, North Carolina State University, Raleigh, North Carolina.
Jacob, Megan E
  • Comparative Medicine Institute, North Carolina State University, Raleigh, North Carolina.
  • Department of Population Health and Pathobiology, College of Veterinary Medicine, North Carolina State University, Raleigh, North Carolina.
Menegatti, Stefano
  • Comparative Medicine Institute, North Carolina State University, Raleigh, North Carolina.
  • Department of Chemical and Biomolecular Engineering, North Carolina State University, Raleigh, North Carolina.
Ashton Lavoie, R
  • Department of Chemical and Biomolecular Engineering, North Carolina State University, Raleigh, North Carolina.
Schnabel, Lauren V
  • Department of Clinical Sciences, College of Veterinary Medicine, North Carolina State University, Raleigh, North Carolina.
  • Comparative Medicine Institute, North Carolina State University, Raleigh, North Carolina.

MeSH Terms

  • Aminoglycosides / pharmacology
  • Animals
  • Anti-Bacterial Agents / pharmacology
  • Arthritis, Infectious / drug therapy
  • Biofilms / drug effects
  • Female
  • Horses
  • Male
  • Molecular Weight
  • Platelet-Rich Plasma
  • Synovial Fluid / microbiology

Grant Funding

  • R01 AR072513 / NIAMS NIH HHS
  • S10 OD021633 / NIH HHS
  • S10 RR027128 / NCRR NIH HHS

References

This article includes 50 references
  1. Morton AJ. Diagnosis and treatment of septic arthritis.. Vet Clin North Am Equine Pract 2005 Dec;21(3):627-49, vi.
    pubmed: 16297725doi: 10.1016/j.cveq.2005.08.001google scholar: lookup
  2. Mathews CJ, Weston VC, Jones A, Field M, Coakley G. Bacterial septic arthritis in adults.. Lancet 2010 Mar 6;375(9717):846-55.
    pubmed: 20206778doi: 10.1016/S0140-6736(09)61595-6google scholar: lookup
  3. Shirtliff ME, Mader JT. Acute septic arthritis.. Clin Microbiol Rev 2002 Oct;15(4):527-44.
    pmc: PMC126863pubmed: 12364368doi: 10.1128/CMR.15.4.527-544.2002google scholar: lookup
  4. Tong SY, Davis JS, Eichenberger E, Holland TL, Fowler VG Jr. Staphylococcus aureus infections: epidemiology, pathophysiology, clinical manifestations, and management.. Clin Microbiol Rev 2015 Jul;28(3):603-61.
    pmc: PMC4451395pubmed: 26016486doi: 10.1128/CMR.00134-14google scholar: lookup
  5. Tande AJ, Patel R. Prosthetic joint infection.. Clin Microbiol Rev 2014 Apr;27(2):302-45.
    pmc: PMC3993098pubmed: 24696437doi: 10.1128/CMR.00111-13google scholar: lookup
  6. Nair R, Schweizer ML, Singh N. Septic Arthritis and Prosthetic Joint Infections in Older Adults.. Infect Dis Clin North Am 2017 Dec;31(4):715-729.
    pubmed: 29079156doi: 10.1016/j.idc.2017.07.013google scholar: lookup
  7. Cobo J, Miguel LG, Euba G, Rodríguez D, García-Lechuz JM, Riera M, Falgueras L, Palomino J, Benito N, del Toro MD, Pigrau C, Ariza J. Early prosthetic joint infection: outcomes with debridement and implant retention followed by antibiotic therapy.. Clin Microbiol Infect 2011 Nov;17(11):1632-7.
    pubmed: 20678178doi: 10.1111/j.1469-0691.2010.03333.xgoogle scholar: lookup
  8. Byren I, Bejon P, Atkins BL, Angus B, Masters S, McLardy-Smith P, Gundle R, Berendt A. One hundred and twelve infected arthroplasties treated with 'DAIR' (debridement, antibiotics and implant retention): antibiotic duration and outcome.. J Antimicrob Chemother 2009 Jun;63(6):1264-71.
    pmc: PMC2680346pubmed: 19336454doi: 10.1093/jac/dkp107google scholar: lookup
  9. Otto M. Staphylococcal biofilms.. Curr Top Microbiol Immunol 2008;322:207-28.
    pmc: PMC2777538pubmed: 18453278doi: 10.1007/978-3-540-75418-3_10google scholar: lookup
  10. Hall-Stoodley L, Stoodley P. Evolving concepts in biofilm infections.. Cell Microbiol 2009 Jul;11(7):1034-43.
    pubmed: 19374653doi: 10.1111/j.1462-5822.2009.01323.xgoogle scholar: lookup
  11. Bjarnsholt T, Alhede M, Alhede M, Eickhardt-Sørensen SR, Moser C, Kühl M, Jensen PØ, Høiby N. The in vivo biofilm.. Trends Microbiol 2013 Sep;21(9):466-74.
    pubmed: 23827084doi: 10.1016/j.tim.2013.06.002google scholar: lookup
  12. Dastgheyb S, Parvizi J, Shapiro IM, Hickok NJ, Otto M. Effect of biofilms on recalcitrance of staphylococcal joint infection to antibiotic treatment.. J Infect Dis 2015 Feb 15;211(4):641-50.
    pmc: PMC4318921pubmed: 25214518doi: 10.1093/infdis/jiu514google scholar: lookup
  13. Dastgheyb SS, Hammoud S, Ketonis C, Liu AY, Fitzgerald K, Parvizi J, Purtill J, Ciccotti M, Shapiro IM, Otto M, Hickok NJ. Staphylococcal persistence due to biofilm formation in synovial fluid containing prophylactic cefazolin.. Antimicrob Agents Chemother 2015 Apr;59(4):2122-8.
    pmc: PMC4356782pubmed: 25624333doi: 10.1128/AAC.04579-14google scholar: lookup
  14. Perez K, Patel R. Biofilm-like aggregation of Staphylococcus epidermidis in synovial fluid.. J Infect Dis 2015 Jul 15;212(2):335-6.
    pmc: PMC4566000pubmed: 25712965doi: 10.1093/infdis/jiv096google scholar: lookup
  15. Gilbertie JM, Schnabel LV, Hickok NJ, Jacob ME, Conlon BP, Shapiro IM, Parvizi J, Schaer TP. Equine or porcine synovial fluid as a novel ex vivo model for the study of bacterial free-floating biofilms that form in human joint infections.. PLoS One 2019;14(8):e0221012.
    pmc: PMC6695105pubmed: 31415623doi: 10.1371/journal.pone.0221012google scholar: lookup
  16. Stoodley P, Ehrlich GD, Sedghizadeh PP, Hall-Stoodley L, Baratz ME, Altman DT, Sotereanos NG, Costerton JW, Demeo P. Orthopaedic biofilm infections.. Curr Orthop Pract 2011 Nov;22(6):558-563.
    pmc: PMC3272669pubmed: 22323927doi: 10.1097/BCO.0b013e318230efcfgoogle scholar: lookup
  17. Wolcott RD, Ehrlich GD. Biofilms and chronic infections.. JAMA 2008 Jun 11;299(22):2682-4.
    pubmed: 18544729doi: 10.1001/jama.299.22.2682google scholar: lookup
  18. Boswell SG, Cole BJ, Sundman EA, Karas V, Fortier LA. Platelet-rich plasma: a milieu of bioactive factors.. Arthroscopy 2012 Mar;28(3):429-39.
    pubmed: 22284405doi: 10.1016/j.arthro.2011.10.018google scholar: lookup
  19. Moojen DJ, Everts PA, Schure RM, Overdevest EP, van Zundert A, Knape JT, Castelein RM, Creemers LB, Dhert WJ. Antimicrobial activity of platelet-leukocyte gel against Staphylococcus aureus.. J Orthop Res 2008 Mar;26(3):404-10.
    pubmed: 17960651doi: 10.1002/jor.20519google scholar: lookup
  20. López C, Carmona JU, Giraldo CE, Alvarez ME. Bacteriostatic effect of equine pure platelet-rich plasma and other blood products against methicillin-sensitive Staphylococcus aureus. An in vitro study.. Vet Comp Orthop Traumatol 2014;27(5):372-8.
    pubmed: 25088784doi: 10.3415/VCOT-14-04-0054google scholar: lookup
  21. López C, Alvarez ME, Carmona JU. Temporal Bacteriostatic Effect and Growth Factor Loss in Equine Platelet Components and Plasma Cultured with Methicillin-Sensitive and Methicillin-Resistant Staphylococcus aureus: A Comparative In Vitro Study.. Vet Med Int 2014;2014:525826.
    pmc: PMC4260436pubmed: 25506468doi: 10.1155/2014/525826google scholar: lookup
  22. Tang YQ, Yeaman MR, Selsted ME. Antimicrobial peptides from human platelets.. Infect Immun 2002 Dec;70(12):6524-33.
    pmc: PMC132966pubmed: 12438321doi: 10.1128/IAI.70.12.6524-6533.2002google scholar: lookup
  23. Różalski MI, Micota B, Sadowska B, Paszkiewicz M, Więckowska-Szakiel M, Różalska B. Antimicrobial/anti-biofilm activity of expired blood platelets and their released products.. Postepy Hig Med Dosw (Online) 2013 Apr 22;67:321-5.
    pubmed: 23619231doi: 10.5604/17322693.1046009google scholar: lookup
  24. Al-Ajlouni J, Awidi A, Samara O, Al-Najar M, Tarwanah E, Saleh M, Awidi M, Hassan FA, Samih M, Bener A, Dweik M. Safety and Efficacy of Autologous Intra-articular Platelet Lysates in Early and Intermediate Knee Osteoarthrosis in Humans: A Prospective Open-Label Study.. Clin J Sport Med 2015 Nov;25(6):524-8.
    pubmed: 25387167doi: 10.1097/JSM.0000000000000166google scholar: lookup
  25. Tyrnenopoulou P, Diakakis N, Karayannopoulou M, Savvas I, Koliakos G. Evaluation of intra-articular injection of autologous platelet lysate (PL) in horses with osteoarthritis of the distal interphalangeal joint.. Vet Q 2016 Jun;36(2):56-62.
    pubmed: 26828234doi: 10.1080/01652176.2016.1141257google scholar: lookup
  26. Liesenborghs L, Verhamme P, Vanassche T. Staphylococcus aureus, master manipulator of the human hemostatic system.. J Thromb Haemost 2018 Mar;16(3):441-454.
    pubmed: 29251820doi: 10.1111/jth.13928google scholar: lookup
  27. Giraldo CE, López C, Álvarez ME, Samudio IJ, Prades M, Carmona JU. Effects of the breed, sex and age on cellular content and growth factor release from equine pure-platelet rich plasma and pure-platelet rich gel.. BMC Vet Res 2013 Feb 12;9:29.
    pmc: PMC3577464pubmed: 23402541doi: 10.1186/1746-6148-9-29google scholar: lookup
  28. Xiong G, Lingampalli N, Koltsov JCB, Leung LL, Bhutani N, Robinson WH, Chu CR. Men and Women Differ in the Biochemical Composition of Platelet-Rich Plasma.. Am J Sports Med 2018 Feb;46(2):409-419.
    pubmed: 29211968doi: 10.1177/0363546517740845google scholar: lookup
  29. Rinnovati R, Romagnoli N, Gentilini F, Lambertini C, Spadari A. The influence of environmental variables on platelet concentration in horse platelet-rich plasma.. Acta Vet Scand 2016 Jul 4;58(1):45.
    pmc: PMC4932754pubmed: 27377748doi: 10.1186/s13028-016-0226-3google scholar: lookup
  30. Zhang LJ, Gallo RL. Antimicrobial peptides.. Curr Biol 2016 Jan 11;26(1):R14-9.
    pubmed: 26766224doi: 10.1016/j.cub.2015.11.017google scholar: lookup
  31. Sørensen OE, Follin P, Johnsen AH, Calafat J, Tjabringa GS, Hiemstra PS, Borregaard N. Human cathelicidin, hCAP-18, is processed to the antimicrobial peptide LL-37 by extracellular cleavage with proteinase 3.. Blood 2001 Jun 15;97(12):3951-9.
    pubmed: 11389039doi: 10.1182/blood.v97.12.3951google scholar: lookup
  32. Burnouf T, Strunk D, Koh MB, Schallmoser K. Human platelet lysate: Replacing fetal bovine serum as a gold standard for human cell propagation?. Biomaterials 2016 Jan;76:371-87.
    pubmed: 26561934doi: 10.1016/j.biomaterials.2015.10.065google scholar: lookup
  33. Yeaman MR. Platelets: at the nexus of antimicrobial defence.. Nat Rev Microbiol 2014 Jun;12(6):426-37.
    pubmed: 24830471doi: 10.1038/nrmicro3269google scholar: lookup
  34. Li GY, Yin JM, Ding H, Jia WT, Zhang CQ. Efficacy of leukocyte- and platelet-rich plasma gel (L-PRP gel) in treating osteomyelitis in a rabbit model.. J Orthop Res 2013 Jun;31(6):949-56.
    pubmed: 23280538doi: 10.1002/jor.22299google scholar: lookup
  35. Burnouf T, Chou ML, Wu YW, Su CY, Lee LW. Antimicrobial activity of platelet (PLT)-poor plasma, PLT-rich plasma, PLT gel, and solvent/detergent-treated PLT lysate biomaterials against wound bacteria.. Transfusion 2013 Jan;53(1):138-46.
    pubmed: 22563709doi: 10.1111/j.1537-2995.2012.03668.xgoogle scholar: lookup
  36. Bielecki TM, Gazdzik TS, Arendt J, Szczepanski T, Król W, Wielkoszynski T. Antibacterial effect of autologous platelet gel enriched with growth factors and other active substances: an in vitro study.. J Bone Joint Surg Br 2007 Mar;89(3):417-20.
    pubmed: 17356164doi: 10.1302/0301-620X.89B3.18491google scholar: lookup
  37. Textor JA, Tablin F. Activation of equine platelet-rich plasma: comparison of methods and characterization of equine autologous thrombin.. Vet Surg 2012 Oct;41(7):784-94.
    pubmed: 22742830doi: 10.1111/j.1532-950X.2012.01016.xgoogle scholar: lookup
  38. Yeaman MR. Bacterial-platelet interactions: virulence meets host defense.. Future Microbiol 2010 Mar;5(3):471-506.
    pubmed: 20210555doi: 10.2217/fmb.09.112google scholar: lookup
  39. Etulain J, Mena HA, Meiss RP, Frechtel G, Gutt S, Negrotto S, Schattner M. An optimised protocol for platelet-rich plasma preparation to improve its angiogenic and regenerative properties.. Sci Rep 2018 Jan 24;8(1):1513.
    pmc: PMC5784112pubmed: 29367608doi: 10.1038/s41598-018-19419-6google scholar: lookup
  40. Yeaman MR, Norman DC, Bayer AS. Staphylococcus aureus susceptibility to thrombin-induced platelet microbicidal protein is independent of platelet adherence and aggregation in vitro.. Infect Immun 1992 Jun;60(6):2368-74.
    pmc: PMC257167pubmed: 1587603doi: 10.1128/iai.60.6.2368-2374.1992google scholar: lookup
  41. Yeaman MR, Tang YQ, Shen AJ, Bayer AS, Selsted ME. Purification and in vitro activities of rabbit platelet microbicidal proteins.. Infect Immun 1997 Mar;65(3):1023-31.
    pmc: PMC175084pubmed: 9038312doi: 10.1128/IAI.65.3.1023-1031.1997google scholar: lookup
  42. Drago L, Bortolin M, Vassena C, Romanò CL, Taschieri S, Del Fabbro M. Plasma components and platelet activation are essential for the antimicrobial properties of autologous platelet-rich plasma: an in vitro study.. PLoS One 2014;9(9):e107813.
    pmc: PMC4169456pubmed: 25232963doi: 10.1371/journal.pone.0107813google scholar: lookup
  43. Trier DA, Gank KD, Kupferwasser D, Yount NY, French WJ, Michelson AD, Kupferwasser LI, Xiong YQ, Bayer AS, Yeaman MR. Platelet antistaphylococcal responses occur through P2X1 and P2Y12 receptor-induced activation and kinocidin release.. Infect Immun 2008 Dec;76(12):5706-13.
    pmc: PMC2583569pubmed: 18824536doi: 10.1128/IAI.00935-08google scholar: lookup
  44. Zapotoczna M, O'Neill E, O'Gara JP. Untangling the Diverse and Redundant Mechanisms of Staphylococcus aureus Biofilm Formation.. PLoS Pathog 2016 Jul;12(7):e1005671.
    pmc: PMC4956047pubmed: 27442433doi: 10.1371/journal.ppat.1005671google scholar: lookup
  45. Gilbertie JM, Long JM, Schubert AG, Berglund AK, Schaer TP, Schnabel LV. Pooled Platelet-Rich Plasma Lysate Therapy Increases Synoviocyte Proliferation and Hyaluronic Acid Production While Protecting Chondrocytes From Synoviocyte-Derived Inflammatory Mediators.. Front Vet Sci 2018;5:150.
    pmc: PMC6039577pubmed: 30023361doi: 10.3389/fvets.2018.00150google scholar: lookup
  46. Scheer FA, Michelson AD, Frelinger AL 3rd, Evoniuk H, Kelly EE, McCarthy M, Doamekpor LA, Barnard MR, Shea SA. The human endogenous circadian system causes greatest platelet activation during the biological morning independent of behaviors.. PLoS One 2011;6(9):e24549.
    pmc: PMC3169622pubmed: 21931750doi: 10.1371/journal.pone.0024549google scholar: lookup
  47. Naskou MC, Norton NA, Copland IB, Galipeau J, Peroni JF. Innate immune responses of equine monocytes cultured in equine platelet lysate.. Vet Immunol Immunopathol 2018 Jan;195:65-71.
    pubmed: 29249319doi: 10.1016/j.vetimm.2017.11.005google scholar: lookup
  48. Dosler S, Mataraci E. In vitro pharmacokinetics of antimicrobial cationic peptides alone and in combination with antibiotics against methicillin resistant Staphylococcus aureus biofilms.. Peptides 2013 Nov;49:53-8.
    pubmed: 23988790doi: 10.1016/j.peptides.2013.08.008google scholar: lookup
  49. Grassi L, Maisetta G, Esin S, Batoni G. Combination Strategies to Enhance the Efficacy of Antimicrobial Peptides against Bacterial Biofilms.. Front Microbiol 2017;8:2409.
    pmc: PMC5770624pubmed: 29375486doi: 10.3389/fmicb.2017.02409google scholar: lookup
  50. Mercier RC, Dietz RM, Mazzola JL, Bayer AS, Yeaman MR. Beneficial influence of platelets on antibiotic efficacy in an in vitro model of Staphylococcus aureus-induced endocarditis.. Antimicrob Agents Chemother 2004 Jul;48(7):2551-7.
    pmc: PMC434186pubmed: 15215108doi: 10.1128/AAC.48.7.2551-2557.2004google scholar: lookup

Citations

This article has been cited 11 times.
  1. Torres LEC, Florez CO, Oliveira JG, Vieira GD, Ribeiro IS, Keller KM, Leme FOP, Fantini P, Maranhão RPA. Antimicrobial Activity of Plasma Rich in Platelets (PRP) on the Ocular Microbiota of Healthy Horses from Minas Gerais: In Vitro Study.. Vet Med Int 2023;2023:2407768.
    doi: 10.1155/2023/2407768pubmed: 37622165google scholar: lookup
  2. Frias-De-Diego A, Gilbertie JM, Scholle F, Dejarnette S, Crisci E. Effect of BIO-PLY(TM), a Platelet-Rich Plasma Derived Biologic on PRRSV-2-Infected Macrophages.. Viruses 2022 Nov 28;14(12).
    doi: 10.3390/v14122666pubmed: 36560670google scholar: lookup
  3. Pezzanite LM, Chow L, Phillips J, Griffenhagen GM, Moore AR, Schaer TP, Engiles JB, Werpy N, Gilbertie J, Schnabel LV, Antczak D, Miller D, Dow S, Goodrich LR. TLR-activated mesenchymal stromal cell therapy and antibiotics to treat multi-drug resistant Staphylococcal septic arthritis in an equine model.. Ann Transl Med 2022 Nov;10(21):1157.
    doi: 10.21037/atm-22-1746pubmed: 36467344google scholar: lookup
  4. Nadra M, Niu W, Kurisawa M, Rousson D, Spector M. Platelet-Rich Plasma Lysate-Incorporating Gelatin Hydrogel as a Scaffold for Bone Reconstruction.. Bioengineering (Basel) 2022 Sep 29;9(10).
    doi: 10.3390/bioengineering9100513pubmed: 36290482google scholar: lookup
  5. Gilbertie JM, Schaer TP, Engiles JB, Seiler GS, Deddens BL, Schubert AG, Jacob ME, Stefanovski D, Ruthel G, Hickok NJ, Stowe DM, Frink A, Schnabel LV. A Platelet-Rich Plasma-Derived Biologic Clears Staphylococcus aureus Biofilms While Mitigating Cartilage Degeneration and Joint Inflammation in a Clinically Relevant Large Animal Infectious Arthritis Model.. Front Cell Infect Microbiol 2022;12:895022.
    doi: 10.3389/fcimb.2022.895022pubmed: 35711655google scholar: lookup
  6. Akeda K, Takegami N, Yamada J, Fujiwara T, Ohishi K, Tamaru S, Sudo A. Platelet-Rich Plasma-Releasate (PRPr) for the Treatment of Discogenic Low Back Pain Patients: Long-Term Follow-Up Survey.. Medicina (Kaunas) 2022 Mar 16;58(3).
    doi: 10.3390/medicina58030428pubmed: 35334604google scholar: lookup
  7. Avellar HK, Lutter JD, Ganta CK, Beard W, Smith JR, Jonnalagadda N, Peloquin S, Kang Q, Ayub K. In vitro antimicrobial activity of equine platelet lysate and mesenchymal stromal cells against common clinical pathogens.. Can J Vet Res 2022 Jan;86(1):59-64.
    pubmed: 34975224
  8. Attili AR, Iacoucci C, Serri E, Cuteri V, Cantalamessa A, Linardi M, Rifici C, Mazzullo G, Rossi G, Galosi L, Tambella AM. Antibacterial Properties of Canine Platelet-Rich Plasma and Other Non-Transfusional Hemo-Components: An in vitro Study.. Front Vet Sci 2021;8:746809.
    doi: 10.3389/fvets.2021.746809pubmed: 34671662google scholar: lookup
  9. Wang J, Wang L. Novel therapeutic interventions towards improved management of septic arthritis.. BMC Musculoskelet Disord 2021 Jun 9;22(1):530.
    doi: 10.1186/s12891-021-04383-6pubmed: 34107951google scholar: lookup
  10. Segabinazzi LGTM, Canisso IF, Podico G, Cunha LL, Novello G, Rosser MF, Loux SC, Lima FS, Alvarenga MA. Intrauterine Blood Plasma Platelet-Therapy Mitigates Persistent Breeding-Induced Endometritis, Reduces Uterine Infections, and Improves Embryo Recovery in Mares.. Antibiotics (Basel) 2021 Apr 23;10(5).
    doi: 10.3390/antibiotics10050490pubmed: 33922743google scholar: lookup
  11. Pezzanite L, Chow L, Piquini G, Griffenhagen G, Ramirez D, Dow S, Goodrich L. Use of in vitro assays to identify antibiotics that are cytotoxic to normal equine chondrocytes and synovial cells.. Equine Vet J 2021 May;53(3):579-589.
    doi: 10.1111/evj.13314pubmed: 32544273google scholar: lookup
Subscribe to our newsletter
Join 99,359 horse owners like you who receive our email updates on horse health and nutrition.